Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 25 - 26, 2026!

For more Information and Register: Delaware ACC By the Sea: 2026 Chapter Meeting

Download the Brochure: Brochure

Delaware Chapter of the American College of Cardiology


Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS feed: Latest in Cardiology from ACC.org Latest in Cardiology from ACC.org

  • AHA 2026 Trials Examine Strategies to Improve Patient Care Post-Stroke
    From tackling blood clots to managing blood pressure (BP), three separate trials presented at AHA 2026 – REDUCE, OCEANIC-STROKE and OPTIMAL-STROKE – offer new insights into improving outcomes after stroke.
  • Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a)
    Pelacarsen did not result in a lower risk of major adverse cardiovascular events compared with placebo in patients with preexisting cardiovascular disease and high lipoprotein(a) (Lp(a)) over a median follow-up period of approximately five years, based on findings from the Lp(a) HORIZON trial presented at AHA 2026 and simultaneously published in NEJM.
  • ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation
    Anti-inflammatory therapy targeting interleukin-6 (IL-1β) with ziltivekimab (a monoclonal antibody) did not lower risks of cardiovascular events compared with placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and systemic inflammation, based on findings from the ZEUS trial presented at AHA 2026 and simultaneously published in NEJM.
  • Kamala Tamirisa, MD, FACC, Named Next ACC BOG Chair-Elect
    The ACC has announced Kamala Tamirisa, MD, FACC, as the next chair-elect of the ACC Board of Governors (BOG). Tamirisa, who serves as the associate professor of internal medicine in the Division of Cardiology and director of electrophysiology research at UT Southwestern Medical Center in Dallas, TX, is currently governor of the ACC Texas Chapter […]
  • New Insights Across CV Medicine Take Center Stage in JACC Journals at AHA 2026
    Several studies from AHA 2026 exploring topics like precision screening for elevated lipoprotein(a), emerging cardio-oncology biomarkers, translational models for hypertrophic cardiomyopathy (HCM), and sex differences in heart failure (HF) are among the simultaneous publications included in JACC Journals.